Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19470000 | 0.91 | OPRM1 (0.44) | NPSR1OPRM1NPC1RAB9ACA12 | |
| SCHEMBL3887512 | 0.85 | AKT1 (0.39) | NPSR1OPRM1SLC6A4 | |
| SCHEMBL5592301 | 0.78 | CTSD (0.37) | NPSR1OPRM1NPC1RAB9ACA12 | |
| SCHEMBL4201868 | 0.78 | MEN1 (0.50) | NPSR1OPRM1SLC6A2SLC6A4CTSD | |
| SCHEMBL30463552 | 0.77 | OPRM1 (0.41) | NPSR1OPRM1NPC1RAB9ACYP2D6 | |
| SCHEMBL1785929 | 0.75 | NPSR1 (0.45) | NPSR1NPC1RAB9ACA12CA9 | |
| SCHEMBL16728416 | 0.74 | NPSR1 (0.44) | NPSR1NPC1RAB9ACA12CA9 | |
| SCHEMBL16728415 | 0.74 | NPSR1 (0.44) | NPSR1NPC1RAB9ACA12CA9 | |
| SCHEMBL16728439 | 0.74 | NPSR1 (0.44) | NPSR1NPC1RAB9ACA12CA9 | |
| Hydrochloric Acid SCHEMBL28285338 | 0.73 | OPRM1 (0.40) | NPSR1OPRM1NPC1RAB9ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007117482-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | claimed |
| US-20240166645-A1 | PYRIDOPYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2024-05-23 | — | — | US | disclosed |
| EP-4289843-A1 | PYRIDOPYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-12-13 | — | — | EP | disclosed |
| WO-2007117482-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166645-A1 | PYRIDOPYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | SOS1, WEE1, SOS2 | NPSR1 669/4885OPRM1 1790/4885NPC1 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.